Please login to the form below

Not currently logged in
Email:
Password:

Apitope strengthens its board with new director

Dr William Jenkins joins the board following a 30-year career in clinical medicine

Dr William JenkinsClinical stage biotech Apitope has appointed Dr William Jenkins as its independent, non-executive director to its board.

Dr Jenkins has a wealth of pharmaceutical industry experience following a 30-year career in clinical medicine and research.

He has also served on several boards including Ablynx, Evotec and Acambis.

Stéphane Verdood, chairman of the board, said: “We are pleased to welcome William to Apitope’s board of directors.

“William’s extensive drug development expertise is a valuable addition as we seek to advance development of our potential first-in-class antigen-specific treatments targeted at autoimmune diseases.

“William has advised companies through various stages of growth to maturity and I know he will provide further strength and depth to the board.”

22nd March 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics